Form 4: Amicus Therapeutics CEO Bradley L. Campbell Reports Stock Transaction
SEC Form 4 Filing
Bradley L. Campbell, President and CEO of Amicus Therapeutics, reports the disposition of 13,375 shares of common stock on March 15, 2025.
Summary
- On March 15, 2025, Bradley L. Campbell, the President and CEO of Amicus Therapeutics, disposed of 13,375 shares of common stock.
- The transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Campbell directly owns 1,137,282 shares of Amicus Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a stock transaction, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies.
Stakeholder Impact
- The transaction may have a minor impact on shareholder sentiment, depending on how it's perceived.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Date of stock transaction |
| 03/18/2025 | Date of signature on the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.